참고문헌
- Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697-728. https://doi.org/10.1128/CMR.17.4.697-728.2004
- Sztrymf B, Jacobs F, Fichet J, Hamzaoui O, Prat D, Avenel A, et al. Myco plasma-related pneumonia: a rare cause of acute respiratory distress syndrome (ARDS) and of potential antibiotic resistance. Rev Mal Respir 2013;30:77-80. https://doi.org/10.1016/j.rmr.2012.06.012
- Wang RS, Wang SY, Hsieh KS, Chiou YH, Huang IF, Cheng MF, et al. Necrotizing pneumonitis caused by Mycoplasma pneumoniae in pediatric patients: report of five cases and review of literature. Pediatr Infect Dis J 2004;23:564-7. https://doi.org/10.1097/01.inf.0000130074.56368.4b
- Shen Y, Zhang J, Hu Y, Shen K. Combination therapy with immune- modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection: a case report. Pediatr Pulmonol 2013;48:519-22. https://doi.org/10.1002/ppul.22650
- Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979;139: 681-7. https://doi.org/10.1093/infdis/139.6.681
- Kim EK, Youn YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr 2015; 58:172-7. https://doi.org/10.3345/kjp.2015.58.5.172
- Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae Infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol 2016;7:693.
- Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013;19:1281-4. https://doi.org/10.3201/eid1908.121455
- Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78-86. https://doi.org/10.1007/s10156-009-0021-4
- Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, et al. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother 2012;56:1108-9. https://doi.org/10.1128/AAC.05627-11
- Kim JH, Kim JY, Yoo CH, Seo WH, Yoo Y, Song DJ, et al. macrolide resistance and its impacts on M. pneumoniae pneumonia in children: comparison of two recent epidemics in Korea. Allergy Asthma Immunol Res 2017;9:340-6. https://doi.org/10.4168/aair.2017.9.4.340
- Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother 2014;20:270-3. https://doi.org/10.1016/j.jiac.2014.01.001
- Seo YH, Kim JS, Seo SC, Seo WH, Yoo Y, Song DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr 2014;57:186-92. https://doi.org/10.3345/kjp.2014.57.4.186
- Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-52. https://doi.org/10.1097/CCM.0B013E318165BABB
- Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73. https://doi.org/10.1183/09031936.00166106
- Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003;35:56-61. https://doi.org/10.1002/ppul.10201
- Shah SS, Florin TA, Ambroggio L. Procalcitonin in childhood pneumonia. J Pediatric Infect Dis Soc 2018;7:54-5. https://doi.org/10.1093/jpids/piw095
- Moulin F, Raymond J, Lorrot M, Marc E, Coste J, Iniguez JL, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001;84:332-6. https://doi.org/10.1136/adc.84.4.332
- Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42-7. https://doi.org/10.3345/kjp.2012.55.2.42
- Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18.
- Yang HJ, Song DJ, Shim JY. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2017;60:167-74. https://doi.org/10.3345/kjp.2017.60.6.167
- Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 2014;58:1034-8. https://doi.org/10.1128/AAC.01806-13
- Cheong KN, Chiu SS, Chan BW, To KK, Chan EL, Ho PL. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect 2016;49:127-30. https://doi.org/10.1016/j.jmii.2014.11.003
- Maniaci V, Dauber A, Weiss S, Nylen E, Becker KL, Bachur R. Procalcitonin in young febrile infants for the detection of serious bac- terial infections. Pediatrics 2008;122:701-10. https://doi.org/10.1542/peds.2007-3503
- Hoshina T, Nanishi E, Kanno S, Nishio H, Kusuhara K, Hara T. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother 2014;20:616-20. https://doi.org/10.1016/j.jiac.2014.06.003
- Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc 2018;7:46-53. https://doi.org/10.1093/jpids/piw091
- Korppi M, Don M, Valent F, Canciani M. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Paediatr 2008;97:943-7. https://doi.org/10.1111/j.1651-2227.2008.00789.x
- Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol 2016;7:800.
- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 2015;40:277-83.
- Narita M, Tanaka H. Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae. Pediatr Pulmonol 2007;42:397. https://doi.org/10.1002/ppul.20445
- Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical charac- teristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One 2016;11:e0156465. https://doi.org/10.1371/journal.pone.0156465
피인용 문헌
- Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children vol.71, pp.7, 2018, https://doi.org/10.1093/cid/ciz1059
- Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia vol.14, pp.4, 2018, https://doi.org/10.22207/jpam.14.4.04
- Predictive value of serum lactate dehydrogenase in diagnosis of septic shock in critical pediatric patients: A cross-sectional study vol.10, pp.3, 2018, https://doi.org/10.4103/2221-6189.316674
- Early Confirmation of Mycoplasma pneumoniae Infection by Two Short-Term Serologic IgM Examination vol.11, pp.2, 2018, https://doi.org/10.3390/diagnostics11020353
- Clinical Significance of Pleural Effusion in Mycoplasma pneumoniae Pneumonia in Children vol.10, pp.9, 2021, https://doi.org/10.3390/pathogens10091075
- Significance of Acute Phase Reactants as Prognostic Biomarkers for Pneumonia in Children vol.14, pp.3, 2018, https://doi.org/10.13005/bpj/2232